Physician profile
Ashkan Attaran
NPI 1194043042
$4,536.62
in general payments reported to CMS, 2019-2025
24 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,411 · 2020: $292 · 2021: $654 · 2022: $508 · 2023: $618 · 2024: $563 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,202.49 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $498.52 | 2019-2024 | Farxiga, Lokelma, Andexxa |
| Pfizer INC. | $462.92 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $427.79 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $409.59 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $229.05 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $192.91 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $139.06 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.49 | 2019-2025 | Jardiance |
| Akcea Therapeutics, INC. | $117.07 | 2019-2020 | |
| Biosense Webster, INC. | $88.66 | 2019 | |
| Merck Sharp & Dohme LLC | $83.35 | 2025 | Verquvo |
| Astellas Pharma US INC | $79.99 | 2019 | |
| Abbott Laboratories | $70.59 | 2019-2025 | Mitraclip |
| Alnylam Pharmaceuticals INC. | $69.18 | 2025 | Amvuttra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $67.87 | 2019 | |
| Novo Nordisk INC | $67.34 | 2023-2024 | |
| Boston Scientific Corporation | $45.45 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $36.28 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $34.94 | 2025 | |
| Esperion Therapeutics, INC. | $34.80 | 2021 | |
| Genzyme Corporation | $19.01 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.92 | 2024 | Voquezna |
| Cardiovascular Systems INC. | $15.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashkan Attaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.